NICE (UK) positive for Andembry (garadacimab) for preventing recurrent attacks of hereditary angioedema – CSL Behring

NICE (UK) – Garadacimab can be used as an option to prevent recurrent attacks of hereditary angioedema in people 12 years and over, only if: i) they have 2 or more attacks a month, and ii) the company provides garadacimab according to the commercial arrangement.

Why the committee made these recommendations: Usual treatment for recurrent attacks of hereditary angioedema in people 12 years and over is long-term preventive treatment with berotralstat, C1‑esterase inhibitors (C1‑INHs) or lanadelumab. Clinical trial evidence shows that garadacimab reduces the number of hereditary angioedema attacks and increases the likelihood of freedom from attacks compared with placebo. Indirect comparisons suggest that garadacimab’s clinical effectiveness is the same or better than berotralstat, C1‑INHs or lanadelumab. The most likely cost-effectiveness estimates are within the range that NICE normally considers an acceptable use of NHS resources. So, garadacimab can be used as an option to prevent recurrent attacks of hereditary angioedema in people 12 years and over having 2 or more attacks a month.